Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a new study.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/02/200210112240.htm
No comments:
Post a Comment